Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2002 1
2004 9
2005 7
2006 3
2007 11
2008 5
2009 4
2010 4
2011 4
2012 5
2013 6
2014 10
2015 13
2016 7
2017 3
2018 3
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17704692

86 results

Results by year

Filters applied: . Clear all
Page 1
Hepatitis C in the HIV-infected patient.
McGovern BH. McGovern BH. J Acquir Immune Defic Syndr. 2007 Jul 1;45 Suppl 2:S47-56; discussion S66-7. doi: 10.1097/QAI.0b013e318068d190. J Acquir Immune Defic Syndr. 2007. PMID: 17704692 Review.
Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM; FIPSE LT-HIV Investigators. Castells L, et al. J Hepatol. 2015 Jan;62(1):92-100. doi: 10.1016/j.jhep.2014.07.034. Epub 2014 Aug 13. J Hepatol. 2015. PMID: 25127748
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J; Swiss HIV Cohort Study. Braun DL, et al. PLoS One. 2015 Jul 15;10(7):e0133028. doi: 10.1371/journal.pone.0133028. eCollection 2015. PLoS One. 2015. PMID: 26176696 Free PMC article. Clinical Trial.
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V. Núñez M, et al. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. doi: 10.1097/QAI.0b013e318061b5d9. J Acquir Immune Defic Syndr. 2007. PMID: 17468669 Clinical Trial.
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P. Sulkowski MS, et al. Hepatol Int. 2017 Mar;11(2):188-198. doi: 10.1007/s12072-017-9788-z. Epub 2017 Feb 16. Hepatol Int. 2017. PMID: 28210927 Clinical Trial.
86 results